ABEO Abeona Therapeutics Inc.
Debt Financing ·
Abeona Therapeutics lowered the rate on its senior secured term loan from 13.5% to a fixed 11.75% and gave the Avenue lenders warrants for up to 16,474 shares at $6.07. Its 2024 net loss was $63.7 million, and its 10-K says $98.1 million in year-end cash and investments, plus later at-the-market proceeds, covers at least 12 months from issuance.
Abeona received gross proceeds of $155 million on June 27, 2025. The company says unaudited cash, cash equivalents, restricted cash and short-term investments were approximately $225 million as of June 30, 2025.
The sale closed on June 27, 2025. Abeona says cash and investments were about $225 million as of June 30, 2025, a figure it labels unaudited, and the release again does not name the buyer.
Abeona received the voucher when the FDA approved ZEVASKYN on April 28, 2025. The company says the proceeds give it cash for more than two years of operating expenses, but the release does not name the buyer.
Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. Its lead product, ZEVASKYN (prademagene zamikeracel), received FDA approval on April 28, 2025 as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious genetic skin disease. ZEVASKYN is manufactured at Abeona's cGMP facility in Cleveland, Ohio, and is delivered through qualified treatment centers; as of March 2026 the company had activated 4 such centers and was in discussions with additional ones. Abeona also develops adeno-associated virus (AAV) gene therapies for ophthalmic diseases using its novel AIM capsids, and it licenses and invents capsid technology for a range of rare genetic diseases. The company partners with academic researchers, patient advocacy organizations, caregivers and other biotechnology companies, and it intends to commercialize its other assets either alone or through strategic partnerships.
| Product or program | What it is | Stage |
|---|---|---|
| ZEVASKYN (prademagene zamikeracel) | Autologous cell-based gene therapy for wounds in recessive dystrophic epidermolysis bullosa | approved in the US |
| AIM capsid AAV gene therapies | AAV-based gene therapies for ophthalmic diseases |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $26.8 million | $34.4 million |
| Net income (loss) | $71.2 million | -$63.7 million |
| Cash from operations | -$76.3 million | -$56.0 million |
| Cash and equivalents | $78.4 million | $23.4 million |
| Short-term investments | $113.0 million | $74.4 million |
Our latest story on this, dated Jul 18, 2025: "Abeona Therapeutics cuts term loan rate to 11.75% and issues Avenue warrants". The story links the filing or release it is based on. Read the story.
Abeona Therapeutics Inc. trades under the ticker ABEO on NASDAQ.
Abeona Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:PCJ; LS:A3DMHM; LSE:0H7R; LSX:A3DMHM.
The SEC Central Index Key (CIK) for Abeona Therapeutics Inc. is 318306. Its filings are on SEC EDGAR.
57,184,017 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Abeona Therapeutics Inc. under United States.
Our directory classifies Abeona Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Abeona Therapeutics Inc. is US00289Y2063.
aibio.space lists Abeona Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. Its lead product, ZEVASKYN (prademagene zamikeracel), received FDA approval on April 28, 2025 as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious genetic skin disease.
ZEVASKYN (prademagene zamikeracel): Autologous cell-based gene therapy for wounds in recessive dystrophic epidermolysis bullosa Stage: approved in the US.
AIM capsid AAV gene therapies: AAV-based gene therapies for ophthalmic diseases
Abeona Therapeutics Inc. reported net income of $71.2 million for the fiscal year ended Dec 31, 2025, and used $76.3 million of cash in operations, per its annual report to the SEC.
$26.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio